Amphastar Pharmaceuticals (AMPH) Capital Expenditures (2013 - 2026)

Amphastar Pharmaceuticals has reported Capital Expenditures for 14 years, with the latest figure at $8.6 million in Q2 2026.

• On a quarterly basis, Capital Expenditures fell 18.68% year-over-year to $8.6 million in Q2 2026; TTM through Jun 2026 was $31.7 million, a 33.18% decrease from a year earlier, with the FY2025 full-year figure at $34.9 million, down 15.01% from the prior year.
• Capital Expenditures was $8.6 million for Q2 2026 at Amphastar Pharmaceuticals, down from $9.5 million in the prior quarter.
• The five-year high for Capital Expenditures was $13.8 million in Q3 2024, with the low at $5.3 million in Q3 2025.
• Average Capital Expenditures over 5 years is $8.7 million, with a median of $8.9 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2025: Capital Expenditures jumped 81.27% in 2023, then slumped 61.23% in 2025.
• Over 5 years, Capital Expenditures stood at $6.3 million in 2022, then surged by 49.64% to $9.4 million in 2023, then surged by 31.44% to $12.4 million in 2024, then sank by 33.35% to $8.3 million in 2025, then rose by 3.86% to $8.6 million in 2026.
• The last three Capital Expenditures figures came in at $8.6 million (Q2 2026), $9.5 million (Q1 2026), and $8.3 million (Q4 2025), per Business Quant data.